{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:29:59Z","timestamp":1761895799053,"version":"3.44.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.leukres.2013.11.016","type":"journal-article","created":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T11:30:29Z","timestamp":1385897429000},"page":"310-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Nilotinib 300 mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response"],"prefix":"10.1016","volume":"38","author":[{"given":"Michael E.","family":"O\u2019Dwyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3319-1870","authenticated-orcid":false,"given":"Ronan","family":"Swords","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Frances","family":"McMullin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp D.","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen E.","family":"Langabeer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Alvarez-Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard C.","family":"Woodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eibhlin","family":"Conneally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.11.016_bib0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2141.2011.08603.x","article-title":"Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia","volume":"153","author":"Foroni","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2013.11.016_bib0010","doi-asserted-by":"crossref","first-page":"947","DOI":"10.5858\/2007-131-947-QAOTBT","article-title":"Quantitative assessment of the BCR-ABL transcript using the Cepheid Xpert BCR-ABL Monitor assay","volume":"131","author":"Dufresne","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.leukres.2013.11.016_bib0015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2353\/jmoldx.2007.060112","article-title":"Evaluation of the Cepheid GeneXpert BCR-ABL assay","volume":"9","author":"Jobbagy","year":"2007","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.leukres.2013.11.016_bib0020","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1373\/clinchem.2007.085472","article-title":"Development of an integrated assay for detection of BCR-ABL RNA","volume":"53","author":"Winn-Deen","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.leukres.2013.11.016_bib0025","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3324\/haematol.2010.034389","article-title":"Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost?","volume":"96","author":"Cayuela","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2013.11.016_bib0030","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00277-012-1468-4","article-title":"Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns","volume":"91","author":"Lopez-Jorge","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2013.11.016_bib0035","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.11.016_bib0040","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.11.016_bib0045","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.11.016_bib0050","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.11.016_bib0055","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.11.016_bib0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.leukres.2011.05.010","article-title":"Molecular response to first line nilotinib in a patient with e19a2 BCR-ABL1 chronic myeloid leukemia","volume":"35","author":"Langabeer","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.11.016_bib0065","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","article-title":"Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies","volume":"121","author":"Neelakantan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.11.016_bib0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/PAT.0b013e32834e4203","article-title":"Establishment of a conversion factor for the Cepheid GeneXpert BCR-ABL assay","volume":"44","author":"McNiven","year":"2012","journal-title":"Pathology"},{"issue":"s1","key":"10.1016\/j.leukres.2013.11.016_bib0075","first-page":"237","article-title":"Early Bcr-Abl transcript levels predict future molecular response and long-term outcomes in newly \u2013 diagnosed patients with chronic myeloid leukemia in chronic phase: analysis of ENESTND 3-year data","volume":"97","author":"Hochhaus","year":"2012","journal-title":"Haematologica"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613004177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613004177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:58:27Z","timestamp":1758934707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613004177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0145212613004177"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.11.016","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2013.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}